These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 21478286)

  • 1. Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER).
    Merrill J; Buyon J; Furie R; Latinis K; Gordon C; Hsieh HJ; Brunetta P
    Lupus; 2011 Jun; 20(7):709-16. PubMed ID: 21478286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
    Petri MA; van Vollenhoven RF; Buyon J; Levy RA; Navarra SV; Cervera R; Zhong ZJ; Freimuth WW;
    Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial.
    Tseng CE; Buyon JP; Kim M; Belmont HM; Mackay M; Diamond B; Marder G; Rosenthal P; Haines K; Ilie V; Abramson SB
    Arthritis Rheum; 2006 Nov; 54(11):3623-32. PubMed ID: 17075807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial.
    Merrill JT; Neuwelt CM; Wallace DJ; Shanahan JC; Latinis KM; Oates JC; Utset TO; Gordon C; Isenberg DA; Hsieh HJ; Zhang D; Brunetta PG
    Arthritis Rheum; 2010 Jan; 62(1):222-33. PubMed ID: 20039413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients.
    Garcia-Carrasco M; Mendoza-Pinto C; Sandoval-Cruz M; Soto-Vega E; Beltran-Castillo A; Jimenez-Hernandez M; Graillet D; Gonzalez L; Rojas-Rodriguez J; Pineda-Almazana A; Zamudio-Huerta L; Lopez-Colombo A
    Lupus; 2010 Feb; 19(2):213-9. PubMed ID: 19965944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial.
    Merrill JT; Burgos-Vargas R; Westhovens R; Chalmers A; D'Cruz D; Wallace DJ; Bae SC; Sigal L; Becker JC; Kelly S; Raghupathi K; Li T; Peng Y; Kinaszczuk M; Nash P
    Arthritis Rheum; 2010 Oct; 62(10):3077-87. PubMed ID: 20533545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Definition and treatment of lupus flares measured by the BILAG index.
    Gordon C; Sutcliffe N; Skan J; Stoll T; Isenberg DA
    Rheumatology (Oxford); 2003 Nov; 42(11):1372-9. PubMed ID: 12810926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of flare and influence of demographic and serologic factors on flare risk in systemic lupus erythematosus: a prospective study.
    Petri M; Singh S; Tesfasyone H; Malik A
    J Rheumatol; 2009 Nov; 36(11):2476-80. PubMed ID: 19833757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE).
    Kalunian KC; Merrill JT; Maciuca R; McBride JM; Townsend MJ; Wei X; Davis JC; Kennedy WP
    Ann Rheum Dis; 2016 Jan; 75(1):196-202. PubMed ID: 26038091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Testosterone patches in the management of patients with mild/moderate systemic lupus erythematosus.
    Gordon C; Wallace DJ; Shinada S; Kalunian KC; Forbess L; Braunstein GD; Weisman MH
    Rheumatology (Oxford); 2008 Mar; 47(3):334-8. PubMed ID: 18238794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of rituximab on resistant SLE disease including lung involvement.
    Reynolds JA; Toescu V; Yee CS; Prabu A; Situnayake D; Gordon C
    Lupus; 2009 Jan; 18(1):67-73. PubMed ID: 19074171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients.
    Lu TY; Ng KP; Cambridge G; Leandro MJ; Edwards JC; Ehrenstein M; Isenberg DA
    Arthritis Rheum; 2009 Apr; 61(4):482-7. PubMed ID: 19333973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial.
    Chang DM; Lan JL; Lin HY; Luo SF
    Arthritis Rheum; 2002 Nov; 46(11):2924-7. PubMed ID: 12428233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of biologic therapies for systemic lupus erythematosus treatment: systematic review and meta-analysis.
    Borba HH; Wiens A; de Souza TT; Correr CJ; Pontarolo R
    BioDrugs; 2014 Apr; 28(2):211-28. PubMed ID: 24190520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.
    Leandro MJ; Cambridge G; Edwards JC; Ehrenstein MR; Isenberg DA
    Rheumatology (Oxford); 2005 Dec; 44(12):1542-5. PubMed ID: 16188950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B cell depletion therapy for 19 patients with refractory systemic lupus erythematosus.
    Podolskaya A; Stadermann M; Pilkington C; Marks SD; Tullus K
    Arch Dis Child; 2008 May; 93(5):401-6. PubMed ID: 18039744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of rituximab in a chart review study of 15 patients with systemic lupus erythematosus.
    Hickman RA; Hira-Kazal R; Yee CS; Toescu V; Gordon C
    Clin Rheumatol; 2015 Feb; 34(2):263-71. PubMed ID: 25564308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study.
    Merrill JT; Wallace DJ; Petri M; Kirou KA; Yao Y; White WI; Robbie G; Levin R; Berney SM; Chindalore V; Olsen N; Richman L; Le C; Jallal B; White B;
    Ann Rheum Dis; 2011 Nov; 70(11):1905-13. PubMed ID: 21798883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis.
    Duxbury B; Combescure C; Chizzolini C
    Lupus; 2013 Dec; 22(14):1489-503. PubMed ID: 24135078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tibolone in postmenopausal women with systemic lupus erythematosus: a pilot study.
    Vieira CS; Pereira FV; de Sá MF; Paulo LJ; Martins WP; Ferriani RA
    Maturitas; 2009 Mar; 62(3):311-6. PubMed ID: 19193505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.